Loading...
Acute myocardial infarction following erlotinib treatment for NSCLC: A case report
Erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, is an oral targeted anticancer drug that is used to treat non-small cell lung cancer (NSCLC). Previous studies have confirmed that erlotinib is safe and is well-tolerated by patients. The most common adverse reactions observed...
Saved in:
| Published in: | Oncol Lett |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
D.A. Spandidos
2016
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4888202/ https://ncbi.nlm.nih.gov/pubmed/27313772 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2016.4508 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|